Kirby McInerney LLP | Financial Litigation Law Firm | <h3 >Veru Inc. </h3 >
This links to the home page

Veru Inc. 

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of Florida on behalf of those who acquired Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU) securities between May 11, 2022 through November 9, 2022 (the “Class Period”). Investors have until February 6, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Veru is an oncology and urology biopharmaceutical company developing medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals.
On November 10, 2022, a Food and Drug Administration Advisory Committee voted against recommending Emergency Use Authorization for the Company's COVID-19 pill VERU-111. On this news, the price of Veru shares declined by $8.04 per share, or approximately 53.56%, from $15.01 per share to close at $6.97 on November 10, 2022.
The lawsuit alleges that, throughout the Class Period, Defendants misled investors and/or failed to disclose that that the data from the Phase 3 trial was insufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application ("NDA") without any further studies. VERU's filings therefore concealed the true risks faced by the Company in gaining approval for its EUA request.

Veru Inc. Investor Contact Form